Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma.
CD8+
NGS
cell sorting
flow cytometry
immunohistochemistry
indolent
molecular fingerprinting
multifocal
primary cutaneous T-lymphoma
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
received:
09
01
2023
revised:
03
02
2023
accepted:
16
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
We report the case of a patient who was referred to our institution with a diagnosis of CD4+ small/medium-sized pleomorphic lymphoma. At the time, the patient showed a plethora of lesions mainly localizing to the legs; thus, we undertook studies to investigate the lineage and immunophenotype of the neoplastic clone. Immunohistochemistry (IHC) showed marked CD4 and CD8 positivity. Flow cytometry (FCM) showed two distinct T-cell populations, CD4+ and CD8+ (+/- PD1), with no CD4/CD8 co-expression and no loss of panT-cell markers in either T-cell subset. FCM, accompanied by cell-sorting (CS), permitted the physical separation of four populations, as follows: CD4+/PD1-, CD4+/PD1+, CD8+/PD1- and CD8+/PD1+. TCR gene rearrangement studies on each of the four populations (by next generation sequencing, NGS) showed that the neoplastic population was of T-cytotoxic cell lineage. IHC showed the CD8+ population to be TIA-1+, but perforin- and granzyme-negative. Moreover, histiocytic markers did not render the peculiar staining pattern, which is characteristic of acral CD8+ T-cell lymphoma (PCACD8). Compared to the entities described in the 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, we found that the indolent lymphoma described herein differed from all of them. We submit that this case represents a hitherto-undescribed type of CTCL.
Identifiants
pubmed: 36831170
pii: biomedicines11020634
doi: 10.3390/biomedicines11020634
pmc: PMC9953132
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
Br J Dermatol. 2015 Jun;172(6):1573-1580
pubmed: 25524664
Hematol Oncol. 2021 Jun;39 Suppl 1:46-51
pubmed: 34105822
Clin Exp Dermatol. 2010 Dec;35(8):892-6
pubmed: 20456402
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
J Hematop. 2008 Sep;1(2):97-109
pubmed: 19669208
Nat Rev Cancer. 2020 Jun;20(6):323-342
pubmed: 32249838
Am J Clin Pathol. 2013 Apr;139(4):491-514
pubmed: 23525618
J Cutan Pathol. 2013 Feb;40(2):248-58
pubmed: 23189944
Blood. 2003 May 1;101(9):3407-12
pubmed: 12522013
Mod Pathol. 2008 Jun;21(6):708-15
pubmed: 18311111
Haematologica. 2022 Mar 01;107(3):702-714
pubmed: 33792220
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Am J Surg Pathol. 2004 Jun;28(6):719-35
pubmed: 15166664
J Cutan Pathol. 2010 Jan;37(1):81-4
pubmed: 19602068
Am J Surg Pathol. 2012 Jan;36(1):109-16
pubmed: 21989349
Am J Clin Pathol. 2011 Feb;135(2):278-90
pubmed: 21228369
J Cutan Pathol. 2010 Sep;37(9):977-81
pubmed: 19891656
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
Am J Surg Pathol. 2007 Dec;31(12):1887-92
pubmed: 18043044
Blood. 2008 Jan 15;111(2):838-45
pubmed: 17934071
Cancer. 2003 Feb 1;97(3):610-27
pubmed: 12548603
Am J Dermatopathol. 2014 May;36(5):402-8
pubmed: 24394306
Histopathology. 2015 Oct;67(4):425-41
pubmed: 24438036